GLP-1 weight-loss drugs such as Ozempic, Wegovy, Zepbound and Mounjaro are reshaping the treatment of obesity — and transforming the global pharmaceutical market.

Originally developed to treat type-2 diabetes, these injectable medicines — including semaglutide and tirzepatide — are now widely prescribed for weight loss, with growing evidence they can also reduce the risk of heart disease and stroke.

But in the United States, access to GLP-1 drugs often depends on insurance coverage — and on who can afford to pay.

In this first episode of a three-part Business Daily series on the global weight-loss economy, Sam Fenwick examines the real cost of obesity drugs in the U.S. healthcare system.

How much do GLP-1 medications like Ozempic, Wegovy, Zepbound and Mounjaro actually cost? Are they cost-effective in the long term? And can insurers and employers afford to provide them to millions of Americans living with obesity?

If you’d like to get in touch with the team, our email address is [email protected]

Produced and presented by Sam Fenwick

Business Daily is the home of in-depth audio journalism devoted to the world of money and work. From small startup stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.

Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.

Recent episodes explore the weight-loss drug revolution, the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.

We also feature in-depth interviews with company founders and some of the world's most prominent CEOs.These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.

(Picture: Person standing on weighing scales. Credit: Press Association)